IASO BIOMED
They are a developmental stage biotechnology company primarily focused on developing and commercializing an orally delivered proprietary peptide to treat hypogonadism (low testosterone). Their goal is to recover testosterone levels safely and effectively for patients with low testosterone. They have established a collaboration with the Research Institute of the McGill University Health Centre (RIMUHC), a world class facility located in Montreal, where current research and development activities are being conducted. The research team is led by Dr. Vassilios Papadopoulos, one of their founders and directors, who specializes in the biochemist
IASO BIOMED
Industry:
Biotechnology Health Care
Founded:
2015-01-01
Address:
Centennial, Colorado, United States
Country:
United States
Website Url:
http://www.iasobiomedusa.com
Status:
Active
Contact:
(720) 389-0650
Technology used in webpage:
Network Solutions DNS Network Solutions Email Hosting Muffin Group
Founder
Official Site Inspections
http://www.iasobiomedusa.com
- Host name: 208.91.197.27
- IP address: 208.91.197.27
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Iaso BioMed"
Iaso BioMed - Crunchbase Company Profile & Funding
Iaso BioMed is a developmental stage biotechnology company. They are a developmental stage biotechnology company primarily focused on developing and commercializing an orally …See details»
IASO BioMed Company Profile 2024: Valuation, Funding
IASO BioMed General Information Description. Developer of orally delivered proprietary peptide intended to treat hypogonadism. IASO BioMed is developing a disruptive, first in …See details»
Acesis BioMed US - Overview, News & Similar companies
Nov 13, 2018 Acesis BioMed US contact info: Phone number: (720) 389-0650 Website: www.iasobiomedusa.com What does Acesis BioMed US do? Acesis BioMed US Inc is a …See details»
IASO BioMed Inc - Company Profile and News - Bloomberg Markets
Company profile page for IASO BioMed Inc including stock price, company news, executives, board members, and contact informationSee details»
IASO BioMed - Products, Competitors, Financials, Employees ...
IASO BioMed is a developmental stage biotechnology company focusing on researching and developing drugs and diagnostic tests for products with a large commercial market potential as …See details»
IASO Biotherapeutics - Overview, News & Similar companies
Apr 3, 2024 IASO Bio Announces NMPA's IND Approval for Equecabtagene Autoleucel in Second- and Third-Line Treatment of Multiple Myeloma SHANGHAI and NANJING, China and …See details»
IASO BioMed Announces Addition of Four Members to Its
Nov 13, 2018 Company developing a Next Generation Treatment for Low Testosterone CENTENNIAL, Colo., Nov. 13, 2018 (GLOBE NEWSWIRE) -- IASO BioMed, Inc. (“IASO” or...See details»
IASO Biotherapeutics Secures $108 Million Series C Funding to …
September 16, 2021, PLEASANTON, Calif. & NANJING, SHANGHAI, China – IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company focusing on …See details»
IASO BioMed CEO, Founder, Key Executive Team, Board of …
Explore {IASO BioMed's key management people. Discover current leadership team members including founders, CEO, other executives and board directors.See details»
Overview / ABOUT IASO / IASO，IASO Bio，IASO …
Founded in 2017, IASO Bio is a leading biopharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of cutting-edge cell therapies and biologics.See details»
IASO Biotherapeutics - Crunchbase Company Profile & Funding
IASO Biotherapeutics may be growing as it has recently achieved a significant regulatory milestone and secured substantial venture funding. The company, in collaboration with …See details»
IASO BioTherapeutics（驯鹿生物） - LinkedIn
IASO BioTherapeutics（驯鹿生物） | 1,570 followers on LinkedIn. Transforming innovation into life-changing therapies | IASO Bio is a clinical-stage biopharmaceutical company engaged in …See details»
Cabaletta Bio and IASO Biotherapeutics Announce Exclusive …
Oct 11, 2022 PHILADELPHIA, Pennsylvania and SAN JOSE, California, NANJING and SHANGHAI, China — October 11, 2022 — IASO Biotherapeutics ("IASO Bio"), a clinical-stage …See details»
IASO Biotherapeutics and Innovent Biologics Announced Updated …
Dec 13, 2021 SAN JOSE & SAN FRANCISCO, CALIF., U.S., NANJING & SHANGHAI CHINA, Dec. 13, 2021 – IASO Biotherapeutics (“IASO Bio”), a clinical-stage biopharmaceutical …See details»
IASO BIO Announces New Development Partnership with Umoja …
SAN JOSE, CALIFORNIA, SHANGHAI, NANJING, CHINA, AND SEATTLE, WASHINGTON, January 03, 2024 –IASO Biotherapeutics (“IASO Bio”), a biopharmaceutical company engaged …See details»
IASO Biotherapeutics Announces New Development Partnership
San Diego – January 4, 2024 – Cooley advised IASO Biotherapeutics, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell …See details»
IASO BIO Announces New Development Partnership with Umoja …
Jan 3, 2024 SAN JOSE, Calif., SHANGHAI and NANJING, China, Jan. 3, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company engaged in discovering, …See details»
Umoja Biopharma and IASO Biotherapeutics Announce Research ...
2022.11.21 | IASO，IASO Bio，IASO Biotherapeutics，IASO Biopharma，CT103A， CAR-T， cell therapy，dual-targeted CAR-TSee details»
IASO BIO Announces New Development Partnership with Umoja …
Jan 4, 2024 SAN JOSE, CALIFORNIA, SHANGHAI, NANJING, CHINA, AND SEATTLE, WASHINGTON, January 04, 2024 –IASO Biotherapeutics (“IASO Bio”), a biopharmaceutical …See details»
Umoja Biopharma and IASO Biotherapeutics Announce Research ...
“We believe that developing off-the-shelf therapies using our iCIL platform and IASO’s CARs will pave the way to broader patient access to top-line therapies in hematological malignancies,” …See details»